Relevance of humanized three-dimensional tumor tissue models: a descriptive systematic literature review.
Clinical translation
Metastasis
Systematic literature review
Three-dimensional model
Tissue culture
Tumor
Journal
Cellular and molecular life sciences : CMLS
ISSN: 1420-9071
Titre abrégé: Cell Mol Life Sci
Pays: Switzerland
ID NLM: 9705402
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
11
09
2019
accepted:
30
03
2020
revised:
25
03
2020
pubmed:
15
4
2020
medline:
21
10
2020
entrez:
15
4
2020
Statut:
ppublish
Résumé
Despite numerous advances in tumor screening, diagnosis, and treatment, to date, tumors remain one of the leading causes of death, principally due to metastasis and the physiological damage produced by tumor growth. Among the main limits related to the study of tumor physiology there is the complex and heterogeneity nature of its environment and the absence of relevant, simple and inexpensive models able to mimic the biological processes occurring in patients allowing the correct clinical translation of results. To enhance the understanding of the mechanisms of tumors and to develop and evaluate new therapeutic approaches the set-up of advanced and alternative models is mandatory. One of the more translational approaches seems to be the use of humanized three-dimensional (3D) tissue culture. This model allows to accurately mimic tumor morphology and biology, maintaining the native microenvironment without any manipulation. However, little is still known on the real clinical relevance of these models for the study of tumor mechanisms and for the screening of new therapy. The aim of this descriptive systematic literature review was to evaluate and summarize the current knowledge on human 3D tumor tissue culture models. We reviewed the strategies employed by researchers to set-up these systems, also considering the different approaches and culture conditions used. All these aspects greatly contribute to the existing knowledge on tumors, providing a specific link to clinical scenarios and making the humanized 3D tumor tissue models a more attractive tool both for researchers and clinicians.
Identifiants
pubmed: 32285137
doi: 10.1007/s00018-020-03513-y
pii: 10.1007/s00018-020-03513-y
doi:
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3913-3944Références
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674
pubmed: 21376230
Padma VV (2015) An overview of targeted cancer therapy. Biomedicine (Taipei) 5(4):19
Li XY, Hu SQ, Xiao L (2015) The cancer-associated fibroblasts and drug resistance. Eur Rev Med Pharmacol Sci 19(11):2112–2119
pubmed: 26125276
Helmy KY, Patel SA, Nahas GR, Rameshwar P (2013) Cancer immunotherapy: accomplishments to date and future promise. Ther Deliv 4(10):1307–1320
pubmed: 24116914
Torre LA, Siegel RL, Ward EM, Jemal A (2016) Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Biomark Prev 25(1):16–27
Guan X (2015) Cancer metastases: challenges and opportunities. Acta Pharm Sin B 5(5):402–418
pubmed: 26579471
pmcid: 4629446
Budczies J, von Winterfeld M, Klauschen F, Bockmayr M, Lennerz JK, Denkert C, Wolf T, Warth A, Dietel M, Anagnostopoulos I, Weichert W, Wittschieber D, Stenzinger A (2015) The landscape of metastatic progression patterns across major human cancers. Oncotarget 6(1):570–583
pubmed: 25402435
Nguyen DX, Bos PD, Massagué J (2009) Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9(4):274–284
pubmed: 19308067
Nyga A, Cheema U, Loizidou M (2011) 3D tumour models: novel in vitro approaches to cancer studies. J Cell Commun Signal 5(3):239–248
pubmed: 21499821
pmcid: 3145874
Imamura Y, Mukohara T, Shimono Y, Funakoshi Y, Chayahara N, Toyoda M, Kiyota N, Takao S, Kono S, Nakatsura T, Minami H (2015) Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer. Oncol Rep 33(4):1837–1843
pubmed: 25634491
Stock K, Estrada MF, Vidic S, Gjerde K, Rudisch A, Santo VE, Barbier M, Blom S, Arundkar SC, Selvam I, Osswald A, Stein Y, Gruenewald S, Brito C, van Weerden W, Rotter V, Boghaert E, Oren M, Sommergruber W, Chong Y, de Hoogt R, Graeser R (2016) Capturing tumor complexity in vitro: comparative analysis of 2D and 3D tumor models for drug discovery. Sci Rep 6:28951
pubmed: 27364600
pmcid: 4929472
Das V, Bruzzese F, Konečný P, Iannelli F, Budillon A, Hajdúch M (2015) Pathophysiologically relevant in vitro tumor models for drug screening. Drug Discov Today 20(7):848–855
pubmed: 25908576
Pagani S, Fini M, Giavaresi G, Salamanna F, Borsari V (2015) The active role of osteoporosis in the interaction between osteoblasts and bone metastases. Bone 79:176–182
pubmed: 26057367
Hickman JA, Graeser R, de Hoogt R, Vidic S, Brito C, Gutekunst M, van der Kuip H, IMI PREDECT Consortium (2014) Three-dimensional models of cancer for pharmacology and cancer cell biology: capturing tumor complexity in vitro/ex vivo. Biotechnol J 9(9):1115–1128
pubmed: 25174503
Fong EL, Harrington DA, Farach-Carson MC, Yu H (2016) Heralding a new paradigm in 3D tumor modeling. Biomaterials 108:197–213
pubmed: 27639438
pmcid: 5730082
Kim JB (2005) Three-dimensional tissue culture models in cancer biology. Semin Cancer Biol 15(5):365–377
pubmed: 15975824
Salamanna F, Contartese D, Maglio M, Fini M (2016) A systematic review on in vitro 3D bone metastases models: a new horizon to recapitulate the native clinical scenario? Oncotarget 7(28):44803–44820
pubmed: 27027241
pmcid: 5190136
Salamanna F, Borsari V, Brogini S, Giavaresi G, Parrilli A, Cepollaro S, Cadossi M, Martini L, Mazzotti A, Fini M (2016) An in vitro 3D bone metastasis model by using a human bone tissue culture and human sex-related cancer cells. Oncotarget 7(47):76966–76983
pubmed: 27765913
pmcid: 5363563
Ruggeri BA, Camp F, Miknyoczki S (2014) Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery. Biochem Pharmacol 87(1):150–161
pubmed: 23817077
Basel MT, Narayanan S, Ganta C, Shreshta TB, Marquez A, Pyle M, Hill J, Bossmann SH, Troyer DL (2018) Developing a xenograft human tumor model in immunocompetent mice. Cancer Lett 412:256–263
pubmed: 29054784
Lee NP, Chan CM, Tung LN, Wang HK, Law S (2018) Tumor xenograft animal models for esophageal squamous cell carcinoma. J Biomed Sci 25(1):66
pubmed: 30157855
pmcid: 6116446
Weroha SJ, Becker MA, Enderica-Gonzalez S, Harrington SC, Oberg AL, Maurer MJ, Perkins SE, Al Hilli M, Butler KA, McKinstry S, Fink S, Jenkins RB, Hou X, Kalli KR, Goodman KM, Sarkaria JN, Karlan BY, Kumar A, Kaufmann SH, Hartmann LC, Haluska P (2014) Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clin Cancer Res 20(5):1288–1297
pubmed: 24398046
pmcid: 3947430
Hidalgo M, Amant F, Biankin AV, Budinská E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Mælandsmo GM, Roman-Roman S, Seoane J, Trusolino L, Villanueva A (2014) Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov 4(9):998–1013
pubmed: 25185190
pmcid: 4167608
Park D, Wang D, Chen G, Deng X (2016) Establishment of patient-derived xenografts in mice. Bio Protocol 6(22):e2008
pubmed: 28184379
pmcid: 5293284
Izumchenko E, Meir J, Bedi A, Wysocki PT, Hoque MO, Sidransky D (2016) Patient-derived xenografts as tools in pharmaceutical development. Clin Pharmacol Ther 99(6):612–621
pubmed: 26874468
Liu ET, Bult CJ, Shultz LD (2016) Patient-derived tumor xenografts: why now? JAMA Oncol 2(5):567–568
pubmed: 27055176
Xu X, Farach-Carson MC, Jia X (2014) Three-dimensional in vitro tumor models for cancer research and drug evaluation. Biotechnol Adv 32(7):1256–1268
pubmed: 25116894
pmcid: 4171250
Weeber F, Ooft SN, Dijkstra KK, Voest EE (2017) Tumor organoids as a pre-clinical cancer model for drug discovery. Cell Chem Biol 24(9):1092–1100
pubmed: 28757181
Nath S, Devi GR (2016) Three-dimensional culture systems in cancer research: focus on tumor spheroid model. Pharmacol Ther 163:94–108
pubmed: 27063403
pmcid: 4961208
Salamanna F, Borsari V, Brogini S, Torricelli P, Cepollaro S, Cadossi M, Fini M (2017) A human 3D in vitro model to assess the relationship between osteoporosis and dissemination to bone of breast cancer tumor cells. J Cell Physiol 232(7):1826–1834
pubmed: 27925188
Albritton JL, Miller JS (2017) 3D bioprinting: improving in vitro models of metastasis with heterogeneous tumor microenvironments. Dis Models Mech 10(1):3–14
Benien P, Swami A (2014) 3D tumor models: history, advances and future perspectives. Future Oncol 10(7):1311–1327
pubmed: 24947267
Ishiguro T, Ohata H, Sato A, Yamawaki K, Enomoto T, Okamoto K (2017) Tumor-derived spheroids: relevance to cancer stem cells and clinical applications. Cancer Sci 108(3):283–289
pubmed: 28064442
pmcid: 5378268
Burdett E, Kasper FK, Mikos AG, Ludwig JA (2010) Engineering tumors: a tissue engineering perspective in cancer biology. Tissue Eng Part B Rev 16(3):351–359
pubmed: 20092396
Weiswald LB, Bellet D, Dangles-Marie V (2015) Spherical cancer models in tumor biology. Neoplasia 17(1):1–15
pubmed: 25622895
pmcid: 4309685
Huang BW, Gao JQ (2018) Application of 3D cultured multicellular spheroid tumor models in tumor-targeted drug delivery system research. J Control Release 270:246–259
pubmed: 29233763
Holliday DL, Moss MA, Pollock S, Lane S, Shaaban AM, Millican-Slater R, Nash C, Hanby AM, Speirs V (2013) The practicalities of using tissue slices as preclinical organotypic breast cancer models. J Clin Pathol 66(3):253–255
pubmed: 23076396
Estes JM, Oliver PG, Straughn JM Jr, Zhou T, WangW GWE, Alvarez RD, Stockard CR, LoBuglio AF, Buchsbaum DJ (2007) Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model. Gynecol Oncol 105(2):291–298
pubmed: 17303227
Dong M, Philippi C, Loretz B, Nafee N, Schaefer UF, Friedel G, Ammon-Treiber S, Griese EU, Lehr CM, Klotz U, Mürdter TE (2011) Tissue slice model of human lung cancer to investigate telomerase inhibition by nanoparticle delivery of antisense 2'-O-methyl-RNA. Int J Pharm 419(1–2):33–42
pubmed: 21782910
Karekla E, Liao WJ, Sharp B, Pugh J, Reid H, Quesne JL, Moore D, Pritchard C, MacFarlane M, Pringle JH (2017) Ex vivo explant cultures of non-small cell lung carcinoma enable evaluation of primary tumor responses to anticancer therapy. Can Res 77(8):2029–2039
Meijer TG, Naipal KA, Jager A, van Gent DC (2017) Ex vivo tumor culture systems for functional drug testing and therapy response prediction. Future Sci OA 3(2):FSO190
pubmed: 28670477
pmcid: 5481868
Merz F, Gaunitz F, Dehghani F, Renner C, Meixensberger J, Gutenberg A, Giese A, Schopow K, Hellwig C, Schäfer M, Bauer M, Stöcker H, Taucher-Scholz G, Durante M, Bechmann I (2013) Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments. Neuro Oncol 15(6):670–681
pubmed: 23576601
pmcid: 3661091
Milani C, Welsh J, Katayama ML, Lyra EC, Maciel MS, Brentani MM, Folgueira MA (2010) Human breast tumor slices: a model for identification of vitamin D regulated genes in the tumor microenvironment. J Steroid Biochem Mol Biol 121(1–2):151–155
pubmed: 20307664
van der Kuip H, Mürdter TE, Sonnenberg M, McClellan M, Gutzeit S, Gerteis A, SimonW FritzP, Aulitzky WE (2006) Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment. BMC Cancer 6:86
pubmed: 16603054
pmcid: 1456977
Gerlach MM, Merz F, Wichmann G, Kubick C, Wittekind C, Lordick F, Dietz A, Bechmann I (2014) Slice cultures from head and neck squamous cell carcinoma: a novel test system for drug susceptibility and mechanisms of resistance. Br J Cancer 110(2):479–488
pubmed: 24263061
Kendrick JE, Straughn JM Jr, Oliver PG, Wang W, Nan L, Grizzle WE, Stockard CR, Alvarez RD, Buchsbaum DJ (2008) Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model. Gynecol Oncol 108(3):591–597
pubmed: 18177927
Kern MA, Haugg AM, Eiteneuer E, Konze E, Drebber U, Dienes HP, Breuhahn K, Schirmacher P, Kasper HU (2006) Ex vivo analysis of antineoplastic agents in precision-cut tissue slices of human origin: effects of cyclooxygenase-2 inhibition in hepatocellular carcinoma. Liver Int 26(5):604–612
pubmed: 16762006
Louandre C, Donnadieu J, Lachaier E, Page C, Chauffert B, Galmiche A (2016) Personalization of the medical treatment of solid tumours using patient-derived tumour explants (review). Int J Oncol 48(3):895–899
pubmed: 26783093
Ward C, Meehan J, Mullen P, Supuran C, Dixon JM, Thomas JS, Winum JY, Lambin P, Dubois L, Pavathaneni NK, Jarman EJ, Renshaw L, Um IH, Kay C, Harrison DJ, Kunkler IH, Langdon SP (2015) Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models. Oncotarget 6(28):24856–24870
pubmed: 26259239
pmcid: 4694798
Scaling AL, Prossnitz ER, Hathaway HJ (2014) GPER mediates estrogen-induced signaling and proliferation in human breast epithelial cells and normal and malignant breast. Horm Cancer 5(3):146–160
pubmed: 24718936
pmcid: 4091989
Savage A, Katz E, Eberst A, Falconer RE, Houston A, Harrison DJ, Bown J (2013) Characterising the tumour morphological response to therapeutic intervention: an ex vivo model. Dis Models Mech 6(1):252–260
Rojas PA, May M, Sequeira GR, Elia A, Alvarez M, Martínez P, Gonzalez P, Hewitt S, He X, Perou CM, Molinolo A, Gibbons L, Abba MC, Gass H, Lanari C (2017) Progesterone receptor isoform ratio: a breast cancer prognostic and predictive factor for antiprogestin responsiveness. J Natl Cancer Inst 109(7):317
Rajendran S, O'Hanlon D, Morrissey D, O'Donovan T, O'Sullivan GC, Tangney M (2011) Preclinical evaluation of gene delivery methods for the treatment of loco-regional disease in breast cancer. Exp Biol Med (Maywood) 236(4):423–434
Naipal KA, Verkaik NS, Sánchez H, van Deurzen CH, den Bakker MA, Hoeijmakers JH, Kanaar R, Vreeswijk MP, Jager A, van Gent DC (2016) Tumor slice culture system to assess drug response of primary breast cancer. BMC Cancer 16:78
pubmed: 26860465
pmcid: 4748539
Muthuswamy R, Okada NJ, Jenkins FJ, McGuire K, McAuliffe PF, Zeh HJ, Bartlett DL, Wallace C, Watkins S, Henning JD, Bovbjerg DH, Kalinski P (2017) Epinephrine promotes COX-2-dependent immune suppression in myeloid cells and cancer tissues. Brain Behav Immun 62:78–86
pubmed: 28212885
Knutson TP, Truong TH, Ma S, Brady NJ, Sullivan ME, Raj G, Schwertfeger KL, Lange CA (2017) Post translationally modified progesterone receptors direct ligand-specific expression of breast cancer stem cell-associated gene programs. J Hematol Oncol 10(1):89
pubmed: 28412963
pmcid: 5392969
Katz E, Sims AH, Sproul D, Caldwell H, Dixon MJ, Meehan RR, Harrison DJ (2012) Targeting of Rac GTPases blocks the spread of intact human breast cancer. Oncotarget 3(6):608–619
pubmed: 22689141
pmcid: 3442288
Grosso SH, Katayama ML, Roela RA, Nonogaki S, Soares FA, Brentani H, Lima L, Folgueira MA, Waitzberg AF, Pasini FS, Góes JC, Brentani MM (2013) Breast cancer tissue slices as a model for evaluation of response to rapamycin. Cell Tissue Res 352(3):671–684
pubmed: 23636418
Faversani A, Vaira V, Moro GP, Tosi D, Lopergolo A, Schultz DC, Rivadeneira D, Altieri DC, Bosari S (2014) Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors. Breast Cancer Res 16(3):R55
pubmed: 24886669
pmcid: 4076638
Centenera MM, Hickey TE, Jindal S, Ryan NK, Ravindranathan P, Mohammed H, Robinson JL, Schiewer MJ, Ma S, Kapur P, Sutherland PD, Hoffmann CE, Roehrborn CG, Gomella LG, Carroll JS, Birrell SN, Knudsen KE, Raj GV, Butler LM, Tilley WD (2018) A patient-derived explant (PDE) model of hormone-dependent cancer. Mol Oncol 12(9):1608–1622
pubmed: 30117261
pmcid: 6120230
Carranza-Torres IE, Guzmán-Delgado NE, Coronado-Martínez C, Bañuelos-García JI, Viveros-Valdez E, Morán-Martínez J, Carranza-Rosales P (2015) Organotypic culture of breast tumor explants as a multicellular system for the screening of natural compounds with antineoplastic potential. Biomed Res Int 2015:618021
pubmed: 26075250
pmcid: 4449881
Antoszczak M, Urbaniak A, Delgado M, Maj E, Borgström B, Wietrzyk J, Huczyński A, Yuan Y, Chambers TC, Strand D (2018) Biological activity of doubly modified salinomycin analogs—evaluation in vitro and ex vivo. Eur J Med Chem 156:510–523
pubmed: 30025346
Vaira V, Fedele G, Pyne S, Fasoli E, Zadra G, Bailey D, Snyder E, Faversani A, Coggi G, Flavin R, Bosari S, Loda M (2010) Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc Natl Acad Sci 107(18):8352–8356
pubmed: 20404174
Le Boeuf F, Diallo JS, McCart JA, Thorne S, Falls T, Stanford M, Kanji F, Auer R, Brown CW, Lichty BD, Parato K, Atkins H, Kirn D, Bell JC (2010) Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther 18(5):888–895
pubmed: 20234341
pmcid: 2890112
Centenera MM, Gillis JL, HansonAR JS, Taylor RA, Risbridger GP, Sutherland PD, Scher HI, Raj GV, Knudsen KE, Yeadon T, Resource APCB, Tilley WD, Butler LM (2012) Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Clin Cancer Res 18(13):3562–3570
pubmed: 22573351
Handle F, Puhr M, Schaefer G, Lorito N, Hoefer J, Gruber M, Guggenberger F, Santer FR, Marques RB, van Weerden WM, Claessens F, Erb HHH, Culig Z (2018) The STAT3 inhibitor galiellalactone reduces IL6-mediated AR activity in benign and malignant prostate models. Mol Cancer Ther 17(12):2722–2731
pubmed: 30254184
Köcher S, Beyer B, Lange T, Nordquist L, Volquardsen J, Burdak-Rothkamm S, Schlomm T, Petersen C, Rothkamm K, Mansour WY (2019) A functional ex vivo assay to detect PARP1-EJ repair and radiosensitization by PARP-inhibitor in prostate cancer. Int J Cancer 144(7):1685–1696
pubmed: 30478958
Gu L, Liao Z, Hoang DT, Dagvadorj A, Gupta S, Blackmon S, Ellsworth E, Talati P, Leiby B, Zinda M, Lallas CD, Trabulsi EJ, McCue P, Gomella L, Huszar D, Nevalainen MT (2013) Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer. Clin Cancer Res 19(20):5658–5674
pubmed: 23942095
pmcid: 6021137
Lin HM, Lee BY, Castillo L, Spielman C, Grogan J, Yeung NK, Kench JG, Stricker PD, Haynes AM, Centenera MM, Butler LM, Shreeve SM, Horvath LG, Daly RJ (2018) Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer. Prostate 78(4):308–317
pubmed: 29314097
Liao Z, Gu L, Vergalli J, Mariani SA, De Dominici M, Lokareddy RK, Dagvadorj A, Purushottamachar P, McCue PA, Trabulsi E, Lallas CD, Gupta S, Ellsworth E, Blackmon S, Ertel A, Fortina P, Leiby B, Xia G, Rui H, Hoang DT, Gomella LG, Cingolani G, Njar V, Pattabiraman N, Calabretta B, Nevalainen MT (2015) Structure-based screen identifies a potent small molecule inhibitor of Stat5a/b with therapeutic potential for prostate cancer and chronic myeloid leukemia. Mol Cancer Ther 14(8):1777–1793
pubmed: 26026053
pmcid: 4547362
Maund SL, Nolley R, Peehl DM (2014) Optimization and comprehensive characterization of a faithful tissue culture model of the benign and malignant human prostate. Lab Invest 94(2):208–221
pubmed: 24296879
Maranto C, Udhane V, Hoang DT, Gu L, Alexeev V, Malas K, Cardenas K, Brody JR, Rodeck U, Bergom C, Iczkowski KA, Jacobsohn K, See W, Schmitt SM, Nevalainen MT (2018) STAT5A/B blockade sensitizes prostate cancer to radiation through inhibition of RAD51 and DNA repair. Clin Cancer Res 24(8):1917–1931
pubmed: 29483142
pmcid: 6036914
Nguyen EV, Centenera MM, Moldovan M, Das R, Irani S, Vincent AD, Chan H, Horvath LG, Lynn DJ, Daly RJ, Butler LM (2018) Identification of novel response and predictive biomarkers to Hsp90 inhibitors through proteomic profiling of patient-derived prostate tumor explants. Mol Cell Proteom 17(8):1470–1486
Shafi AA, Schiewer MJ, de Leeuw R, Dylgjeri E, McCue PA, Shah N, Gomella LG, Lallas CD, Trabulsi EJ, Centenera MM, Hickey TE, Butler LM, Raj G, Tilley WD, Cukierman E, Knudsen KE (2018) Patient-derived models reveal impact of the tumor microenvironment on therapeutic response. Eur Urol Oncol 1(4):325–337
pubmed: 30467556
pmcid: 6241309
Talati PG, Gu L, Ellsworth EM, Girondo MA, Trerotola M, Hoang DT, Leiby B, Dagvadorj A, McCue PA, Lallas CD, Trabulsi EJ, Gomella L, Aplin AE, Languino L, Fatatis A, Rui H, Nevalainen MT (2015) Jak2-Stat5a/b signaling induces epithelial-to-mesenchymal transition and stem-like cell properties in prostate cancer. Am J Pathol 185(9):2505–2522
pubmed: 26362718
pmcid: 4597281
van de Merbel AF, van der Horst G, van der Mark MH, van Uhm JIM, van Gennep EJ, Kloen P, Beimers L, Pelger RCM, van der Pluijm G (2018) An ex vivo tissue culture model for the assessment of individualized drug responses in prostate and bladder cancer. Front Oncol 8:400
pubmed: 30333957
pmcid: 6176278
Das A, Henderson F Jr, Lowe S, Wallace GC 4th, Vandergrift WA 3rd, Lindhorst SM, Varma AK, Infinger LK, Giglio P, Banik NL, Patel SJ, Cachia D (2018) Single agent efficacy of the HDAC inhibitor DATS in preclinical models of glioblastoma. Cancer Chemother Pharmacol 82(6):945–952
pubmed: 30209569
Das A, Cheng RR, Hilbert ML, Dixon-Moh YN, Decandio M, Vandergrift WA 3rd, Banik NL, Lindhorst SM, Cachia D, Varma AK, Patel SJ, Giglio P (2015) Synergistic effects of crizotinib and temozolomide in experimental FIG-ROS1 fusion-positive glioblastoma. Cancer Growth Metastasis 8:51–60
pubmed: 26648752
pmcid: 4667559
Parker JJ, Lizarraga M, Waziri A, Foshay KM (2017) A human glioblastoma organotypic slice culture model for study of tumor cell migration and patient-specific effects of anti-invasive drugs. J Vis Exp (125)
Parker JJ, Dionne KR, Massarwa R, Klaassen M, Foreman NK, Niswander L, Canoll P, Kleinschmidt-Demasters BK, Waziri A (2013) Gefitinib selectively inhibits tumor cell migration in EGFR-amplified human glioblastoma. Neuro Oncol 15(8):1048–1057
pubmed: 23749785
pmcid: 3714155
Xu J, Sampath D, Lang FF, Prabhu S, Rao G, Fuller GN, Liu Y, Puduvalli VK (2011) Vorinostat modulates cell cycle regulatory proteins in glioma cells and human glioma slice cultures. J Neuro Oncol 105(2):241–251
Radtke J, Rezaie SG, Kugler Ch, Zabel P, Schultz H, Vollmer E, Goldmann T, Lang DS (2010) Expression analysis of EML4 in normal lung tissue and non-small cell lung cancer (NSCLC) in the absence and presence of chemotherapeutics. Rom J Morphol Embryol 51(4):647–653
pubmed: 21103621
Sirchia SM, Faversani A, Rovina D, Russo MV, Paganini L, Savi F, Augello C, Rosso L, Del Gobbo A, Tabano S, Bosari S, Miozzo M (2016) Epigenetic effects of chromatin remodeling agents on organotypic cultures. Epigenomics 8(3):341–358
pubmed: 26949823
Leithner K, Wohlkoenig C, Stacher E, Lindenmann J, Hofmann NA, Gallé B, Guelly C, Quehenberger F, Stiegler P, Smolle-Jüttner FM, Philipsen S, PopperHH HA, Olschewski A, Olschewski H (2014) Hypoxia increases membrane metallo-endopeptidase expression in a novel lung cancer ex vivo model—role of tumor stroma cells. BMC Cancer 14:40
pubmed: 24460801
pmcid: 3905926
Hattar K, Savai R, Subtil FS, Wilhelm J, Schmall A, Lang DS, Goldmann T, Eul B, Dahlem G, Fink L, Schermuly RT, Banat GA, Sibelius U, Grimminger F, Vollmer E, Seeger W, Grandel U (2013) Endotoxin induces proliferation of NSCLC in vitro and in vivo: role of COX-2 and EGFR activation. Cancer Immunol Immunother 62(2):309–320
pubmed: 22923191
Cohen G, Lecht S, Oron-Herman M, Momic T, Nissan A, Lazarovici P (2013) Near infrared optical visualization of epidermal growth factor receptors levels in COLO205 colorectal cell line, orthotopic tumor in mice and human biopsies. Int J Mol Sci 14(7):14669–14688
pubmed: 23857061
pmcid: 3742266
Cohen G, Lecht S, Arien-Zakay H, Ettinger K, Amsalem O, Oron-Herman M, Yavin E, Prus D, Benita S, Nissan A, Lazarovici P (2012) Bio-imaging of colorectal cancer models using near infrared labeled epidermal growth factor. PLoS ONE 7(11):e48803
pubmed: 23144978
pmcid: 3493605
Ounpuu L, Truu L, Shevchuk I, Chekulayev V, Klepinin A, Koit A, Tepp K, Puurand M, Rebane-Klemm E, Käämbre T (2018) Comparative analysis of the bioenergetics of human adenocarcinoma Caco-2 cell line and postoperative tissue samples from colorectal cancer patients. Biochem Cell Biol 30:1–10
Rajendran S, O'Sullivan GC, O'Hanlon D, Tangney M (2013) Adenovirus-mediated transcriptional targeting of colorectal cancer and effects on treatment-resistant hypoxic cells. Clin Colorectal Cancer 12(3):152–162.e1
pubmed: 23313233
Scherr AL, Gdynia G, Salou M, Radhakrishnan P, Duglova K, Heller A, Keim S, Kautz N, Jassowicz A, Elssner C, He YW, Jaeger D, Heikenwalder M, Schneider M, Weber A, Roth W, Schulze-Bergkamen H, Koehler BC (2016) Bcl-xL is an oncogenic driver in colorectal cancer. Cell Death Dis 7(8):e2342
pubmed: 27537525
pmcid: 5108319
van Geer MA, Kuhlmann KF, Bakker CT, ten Kate FJ, Oude Elferink RP, Bosma PJ (2009) Ex-vivo evaluation of gene therapy vectors in human pancreatic (cancer) tissue slices. World J Gastroenterol 15(11):1359–1366
pubmed: 19294766
pmcid: 2658838
Misra S, Moro CF, Del Chiaro M, Pouso S, Sebestyén A, Löhr M, Björnstedt M, Verbeke CS (2019) Ex vivo organotypic culture system of precision-cut slices of human pancreatic ductal adenocarcinoma. Sci Rep 9(1):2133
pubmed: 30765891
pmcid: 6376017
Bazou D, Maimon N, Gruionu G, Grahovac J, Seano G, Liu H, Evans CL, Munn LL (2018) Vascular beds maintain pancreatic tumour explants for ex vivo drug screening. J Tissue Eng Regen Med 12(1):e318–e322
pubmed: 28568605
ElNaggar AC, Saini U, Naidu S, Wanner R, Sudhakar M, Fowler J, Nagane M, Kuppusamy P, Cohn DE, Selvendiran K (2016) Anticancer potential of diarylidenyl piperidone derivatives, HO-4200 and H-4318, in cisplatin resistant primary ovarian cancer. Cancer Biol Ther 17(10):1107–1115
pubmed: 27415751
pmcid: 5079393
Saini U, Naidu S, ElNaggar AC, Bid HK, Wallbillich JJ, Bixel K, Bolyard C, Suarez AA, Kaur B, Kuppusamy P, Hays J, Goodfellow PJ, Cohn DE, Selvendiran K (2017) Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target. Oncogene 36(2):168–181
pubmed: 27292260
Theodoraki MN, Yerneni S, Sarkar SN, Orr B, Muthuswamy R, Voyten J, Modugno F, Jiang W, Grimm M, Basse PH, Bartlett DL, Edwards RP, Kalinski P (2018) Helicase-driven activation of NFκB-COX2 pathway mediates the immunosuppressive component of dsRNA-driven inflammation in the human tumor microenvironment. Cancer Res 78(15):4292–4302
pubmed: 29853604
pmcid: 6636317
Jørgensen A, Young J, Nielsen JE, Joensen UN, Toft BG, Rajpert-De Meyts E, Loveland KL (2014) Hanging drop cultures of human testis and testis cancer samples: a model used to investigate activin treatment effects in a preserved niche. Br J Cancer 110(10):2604–2614
pubmed: 24781282
pmcid: 4021512
Affolter A, Muller MF, Sommer K, Stenzinger A, Zaoui K, Lorenz K, Wolf T, Sharma S, Wolf J, Perner S, Weber KJ, Freier K, Plinkert PK, Hess J, Weichert W (2016) Targeting irradiation-induced mitogen-activated protein kinase activation in vitro and in an ex vivo model for human head and neck cancer. Head Neck 38(Suppl 1):E2049–E2061
pubmed: 26918677
Bhattacharyya S, Sekar V, Majumder B, Mehrotra DG, Banerjee S, Bhowmick AK, Alam N, Mandal GK, Biswas J, Majumder PK, Murmu N (2017) CDKN2A-p53 mediated antitumor effect of lupeol in head and neck cancer. Cell Oncol (Dordr) 40(2):145–155
Huang P, Zhuang B, Zhang H, Yan H, Xiao Z, Li W, Zhang J, Tang Q, Hu K, Koeffler HP, Wang J, Yin D (2015) Hepatitis B virus X protein (HBx) is responsible for resistance to targeted therapies in hepatocellular carcinoma: ex vivo culture evidence. Clin Cancer Res 21(19):4420–4430
pubmed: 26059188
Casas BS, Adolphe C, Lois P, Navarrete N, Solís N, Bustamante E, Gac P, Cabané P, Gallegos I, Wainwright BJ, Palma V (2017) Downregulation of the Sonic Hedgehog/Gli pathway transcriptional target Neogenin-1 is associated with basal cell carcinoma aggressiveness. Oncotarget 8(48):84006–84018
pubmed: 29137400
pmcid: 5663572
Fiebitz A, Fritsch M, Reichelt U, Ruester C, Chiantera V, Vercellino GF, Darwish A, Schneider A, Mechsner S (2012) Optimized culture conditions for tissue explants of uterine leiomyoma. Clin Lab 58(11–12):1153–1164
pubmed: 23289184
Koerfer J, Kallendrusch S, Merz F, Wittekind C, Kubick C, Kassahun WT, Schumacher G, Moebius C, Gaßler N, Schopow N, Geister D, Wiechmann V, Weimann A, Eckmann C, Aigner A, Bechmann I, Lordick F (2016) Organotypic slice cultures of human gastric and esophagogastric junction cancer. Cancer Med 5(7):1444–1453
pubmed: 27073068
pmcid: 4944870
Bolenz C, Ikinger EM, Ströbel P, Trojan L, Steidler A, Fernández MI, Honeck P, Gabriel U, Weiss C, Grobholz R, Alken P, Michel MS (2009) Topical chemotherapy in human urothelial carcinoma explants: a novel translational tool for preclinical evaluation of experimental intravesical therapies. Eur Urol 56(3):504–511
pubmed: 18691807
Weissinger D, Tagscherer KE, Macher-Göppinger S, Haferkamp A, Wagener N, Roth W (2013) The soluble decoy receptor 3 is regulated by a PI3K-dependent mechanism and promotes migration and invasion in renal cell carcinoma. Mol Cancer 12(1):120
pubmed: 24107265
pmcid: 3852559
Bastos VC, Pereira NB, Diniz MG, Andrade LO, Castro WH, Kitten GT, Gomez RS, Gomes CC (2019) Bringing benign ectomesenchymal odontogenic tumours to the lab: an in vitro study using an organotypic culture model. J Oral Pathol Med 48(2):174–179
pubmed: 30554445
LoRusso PM, Krishnamurthi SS, Rinehart JJ, Nabell LM, Malburg L, Chapman PB, DePrimo SE, Bentivegna S, Wilner KD, Tan W, Ricart AD (2010) Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res 16(6):1924–1937
pubmed: 20215549
Mak G, Soria JC, Blagden SP, Plummer R, Fleming RA, Nebot N, Zhang J, Mazumdar J, Rogan D, Gazzah A, Rizzuto I, Greystoke A, Yan L, Tolson J, Auger KR, Arkenau HT (2019) A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours. Br J Cancer 120(10):975–981
pubmed: 30992546
pmcid: 6735221
Shimizu T, Fukuoka K, Takeda M, Iwasa T, Yoshida T, Horobin J, Keegan M, Vaickus L, Chavan A, Padval M, Nakagawa K (2016) A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 77(5):997–1003
pubmed: 27025608
pmcid: 4844649
Brown NF, Williams M, Arkenau HT, Fleming RA, Tolson J, Yan L, Zhang J, Swartz L, Singh R, Auger KR, Lenox L, Cox D, Lewis Y, Plisson C, Searle G, Saleem A, Blagden S, Mulholland P (2018) A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098. Neuro Oncol 20(12):1634–1642
pubmed: 29788497
pmcid: 6231205
Wood A, George S, Adra N, Chintala S, Damayanti N, Pili R (2019) Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma. Invest New Drugs. https://doi.org/10.1007/s10637-019-00864-7 (Epub ahead of print)
doi: 10.1007/s10637-019-00864-7
pubmed: 31654285
Ferraldeschi R, Attard G, de Bono JS (2013) Novel strategies to test biological hypotheses in early drug development for advanced prostate cancer. Clin Chem 59:75–84
pubmed: 23204221
Bryant J, Sanson-Fisher R, Fradgley E, Regan T, Hobden B, Ackland SP (2015) Oncology patients overwhelmingly support tissue banking. BMC Cancer 15:413
pubmed: 25981796
pmcid: 4438453